CTOs on the Move

Medefil Inc

www.medefil.com

 
Medefil Inc is a Glendale Heights, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.medefil.com
  • 250 Windy Point Dr
    Glendale Heights, IL USA 60139
  • Phone: 630.682.4600

Executives

Name Title Contact Details

Similar Companies

Allegro Ophthalmics

With over 100 years of combined experience, the seasoned leadership team at Allegro Ophthalmics is dedicated to delivering and establishing Integrin Peptide Therapy TM as the next generation pharmaceutical category for the treatment of wet age-related macular degeneration, diabetic retinopathy and diabetic macular edema. The potential to liberate patients from legal blindness to a much improved quality of life sustained by self-sufficient functional vision propels and accelerates our efforts.

Neurana Pharmaceuticals

Neurana Pharmaceuticals is a privately held clinical stage San Diego based specialty pharmaceutical company developing a novel treatment for acute muscle spasms. The Company was founded in 2013 by veteran biotech entrepreneurs David F. Hale and Jeffrey Raser to focus on central nervous system (CNS) diseases and disorders.

KLOwen Braces

The KLOwen Orthodontics System greatly increases orthodontists​ capacity & profitability without compromising quality.

Intra-Cellular Therapies

Intra-Cellular Therapies is a biopharmaceutical company developing novel drugs, leveraging technology from the lab of Nobel laureate Dr. Paul Greengard, for the treatment of neuropsychiatric and neurodegenerative diseases. The Company is developing its lead drug candidate, lumateperone, a first-in-class molecule, which is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer`s disease. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead compound in the PDE platform, ITI-214, a PDE1 inhibitor is being developed for the treatment of CNS and non-CNS indications.

Quotient Sciences

Quotient Sciences is a drug development and manufacturing accelerator supporting customers from candidate selection to commercial launch.